Mainstay Medical appoints Wolfgang Frisch as VP and Managing Director for Germany
Dublin, Ireland: 20 June 2018 - Mainstay Medical International plc ("Mainstay" or the "Company", Euronext Paris: MSTY.PA and Euronext Dublin: MSTY.IE), a medical device company focused on bringing to market ReActiv8®, an implantable restorative neurostimulation system to treat disabling Chronic Low Back Pain, announces that it has appointed industry veteran Wolfgang Frisch as Vice President and Managing Director for Germany, effective 2 July.
Mainstay Medical has launched ReActiv8 in Germany, its first commercial market. Commercialization began in earnest over the last few months, following the Company's fundraising that was completed in February 2018. Mr. Frisch will be instrumental in driving the commercial strategy forward, with a focus on adoption in a select number of high volume spine care centers to develop reference sites.
More info on Mainstay Medical's website.
Next > Green Biologics announces launch of first bio-based acetone nail polish remover to be introduced in Sally Beauty stores nationwide
Previous > Bluebee achieves ISO 13485 Medical Device Quality Standard Certification